Serotype distribution and antimicrobial susceptibility of <i>Streptococcus pneumoniae</i> isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial. | JAC Antimicrob Resist;3(2): dlab057, 2021 Jun. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial.

McCurdy, S P; Sheets, A J; Cammarata, S K; Vidal, J E.

Affiliation

McCurdy SP; Melinta Therapeutics, Morristown, NJ, USA.
Sheets AJ; Melinta Therapeutics, Morristown, NJ, USA.
Cammarata SK; Melinta Therapeutics, Morristown, NJ, USA.
Vidal JE; Emory University, Atlanta, GA, USA.

JAC Antimicrob Resist ; 3(2): dlab057, 2021 Jun.

Article in En | MEDLINE | ID: mdl-34223119

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: JAC Antimicrob Resist Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: JAC Antimicrob Resist Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom